Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Except that is all Elite is proven they can execute. Not sure I'd call Trimipramine that though. More like a breadcrumb wannabe.
And how are those Epic Oxy sales doing that were supposedly going to be a huge boost to the top and bottomline? I think Trimipramine is bringing in more revenue.
Except the only thing he has proven is that he can make BS. Competitors are the ones laughing.
That is ridiculous. Do you know IR functions? Plus, there are only retail holders. Activist retail holder has no definition for IR.
What was the y/y qtr comparison?
For the Board to approve a 20% bump now makes them look more and more competent each day.
Snup's posts are fun to read. I personally get pissed at the lack of accountability on the missed timelines, flubs and self dealing. That is what ticks me off.
That NASDAQ goal has been pushed back farther & farther. He was counting on SequestOx approval a couple years ago to get there. Didn't happen. His ever increasing dilution will make it much harder now.
I want to see one approval prior to another study. There is too much pipeline without any proof to the tech by the FDA. To say "because the FDA didn't say anything about our tech" means they approve it - is pure garbage by omission. It means nothing. Proof is in the pudding starting this week.
My guess - more of the same - nothing, but more smoke. We will probably hear "how well" the generics are doing again by the CFO along with logistical excuses on shipment timing.
What I am really hoping for is a Trimipramine update. I want to hear about all those dying to get their hands on this one.
How about the self-dealing with Mikah? The more ridiculous non-arms length deals deals the CEO does, the more my confidence erodes. Beyond disgusting waste of resources.
Very true, but I actually believe Nasrat here. It is not uncommon for FDA to do this. I have seen it with other pharmas too.
I believe the other commissioners didn't either, which is why the submission requirements changed for Elite.
I interpret this morning's note that Gottlieb is skeptical of ADT claims, which is why post-marketing studies will be required.
Wow. LOL You are now qualified to be Elite's CFO.
University of Phoenix Online
If they actually have a goal of being on the NASDAQ they need to clean this up by getting a real CFO who understands finance and accounting, and need to implement the appropriate separation of duties and controls.
However, if the company is seeking to be bought out then there is no need to worry about this. This is the direction that I think they are going, for better or for worse.
Accounting error from a couple years ago in misstating revenue was from pure inadequacy. This is more from lack of people infrastructure in not having enough headcount or not knowing who can/can't do what duties.
Because accountability surely isn't important along with adding value and not wasting cash resources. Lol
Of course the company will announce it approved or declined by the FDA as that is a major event and the company is required to do so. No one is arguing the contrary. My comment was to not expect any update at this CC regarding Percocet.
Don't count on it. That update, for better or worse, will be a one-off 8-k.
Please enlighten us of the last time the stock price rose after a conference call? I'll give you a hint: The CEO opens his mouth and the stock does this [fill in the blank].
Milestones have the same impact in 2017 as they do in 2016. There is no change. Revenue is spread over tenure of agreement with Epic. Now If that Epic agreement comes to an end, you can play an accounting trick and have the remaining amount booked as revenue, similar to writing off remaining book depreciation when selling assets. I wouldn't be surprised to see this sleight of hand at some point.
Yes, one or the other.
Multi-million decrease? They are barely doing multi-million on a quarterly basis. That isn't even possible unless all shipments were put on hold for the quarter. Completely unrealistic.
Revenues have consistently increased, but at a significantly decreasing rate. Last quarter barely eeked out a 6% y/y increase. It was the 2nd consecutive quarter blaming timing of shipping. When companies blame timing, they have lost focus on operational & top line improvements.
I would not be surprised to see a revenue decrease compared to last year.
Perhaps the backlogged demand in Trimipramine saved the day? Lol
Another massive 6% spike?
This is the biggest freaking joke I have ever heard. Please share what the total revenues are for this drug. Hint: it is in the worthless category unless you can self-deal.
Um no they can't. Generic business is around for a reason - because it is cheaper than the brand name. Even if they could charge higher than the brand name, the revenues are so paltry, the only person smiling is Nasrat.
Hammerlock on generic Trimipramine is nothing to brag about. Will profits reach into the dollars or tens of dollars. Complete joke.
Biggest fake news of the day! Lol
Not when you insinuate approval is guaranteed.
I believe you often state green lighted to approval, which is 100% incorrect. The ability to progress in trials has been permitted, but nothing more. It all means nothing until we actually get an FDA approval on the technology. We may be getting close and think we are within months rather than weeks as some would like to believe.
Maz - Epic's update on Oxy IR -
Per the Feb 10-Q:
On page 4, but is really like around page 29 after the F pages (financial section). Last sentence is the real update.
"Oxycodone 5mg, Oxycodone 10mg, Oxycodone 15mg, Oxycodone 20mg and Oxycodone 30mg (“Oxy IR”)
We received notification from Epic in October 2015 of the approval by the FDA of Epic’s ANDA for Oxy IR. This product was an Identified IR Product in the Epic Strategic Alliance Agreement Dated March 18, 2009 (the “Epic Strategic Alliance”). Oxy IR was developed at the Northvale Facility pursuant to the Epic Strategic Alliance, in which we are entitled to a Product Fee of 15% of Profits as defined in the Epic Strategic Alliance.
Epic advised us that the first commercial sale of Oxy IR occurred in March 2016 and such sales are ongoing."
Hope that helps.
Great post, thanks Maz. Per the Epic launch of Oxy I will quote the sentence & page from the Q. It was literally only a one liner that it had launched last year.
Except half your comment is BS. We know the Opana part is true though.
Perhaps naivety lured them into the extremely optimist scenario that no one would actually inject Opana. I was less worried about the 8 than I was in the FDA actually approving it.
Overreaction. Market always overreacts one way or the other and will correct itself. Endo is what a $3 billion dollar organization. Opana sales have been decreasing and I believe were recently less than 150M annualized.
Happy to see the FDA act in the best interest of society for a change in lieu of BP.
400K on the ask. Another dumping day.
Why do you not think it was LPC selling? That is what S-3 doc was for.
I believe this was answered a while back that the primary focus is US and getting to see if the tech can get through the FDA. For the most part other countries are more lax once FDA has approved. But if not, I can see them making this attempt to both Canada, Europe & China.